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ABSTRACT
ANALYSIS OF METABOLITES AND THERAPEUTICS FOR TOXIC INHALED
AGENT EXPOSURE
ABIGAIL BEMAH DONKOR
2021
The inhalation of toxic inhaled agents (TIAs) such as methyl isocyanate and cyanide can
compromise an individual’s general health due to their extremely toxic nature.
Nonetheless, these gases are used extensively in the electronics, chemical, welding,
electroplating industries, etc., increasing the risk of exposure to both civilians and industrial
workers. It is therefore very crucial to develop analytical methods for TIA metabolites and
therapeutic agents. Methyl isocyanate (MIC), an intermediate in the synthesis of carbamate
pesticides is a toxic industrial chemical that causes irritation and damage to the eyes,
respiratory tracts, and skin. Due to its reactivity with proteins, protein adducts can be used
to confirm exposure, but this type of analysis is cumbersome, time consuming and
expensive. Hence, we investigated the interaction between MIC and proteins to identify a
novel marker, phenyl methyl carbamate (PMC) based on hydrolysis of tyrosine-MIC
adducts. A simple base hydrolysis was used for sample preparation with sensitive HPLCMS/MS analysis of this marker. The method produced excellent sensitivity for PMC with
a detection limit of 0.02 mg/kg and calibration curve linearity extending from 0.06‒1.51
mg/kg (R2 = 0.998 and overall %RA >90). The accuracy and precision (100±9% and <10%
relative standard deviation, respectively) of the method were outstanding. The validated
method was successfully able to detect elevated levels of PMC from MIC-spiked
hemoglobin and further used to detect significantly elevated PMC levels from hemoglobin
isolated from MIC-exposed rats.

xvi

Sodium-2-mercaptoethane sulfonate (MESNA), has been suggested as a potential
antidote for MIC exposure. It has previously proven to be effective in inactivating acrolein,
the toxic metabolite of anti-tumor drugs (cyclophosphamide and ifosphamide). However,
current methods available to analyze MESNA have limitations, including low sensitivity,
poor selectivity, high degree of difficulty, and many time-consuming steps. Hence, we
developed and validated a simple and selective HPLC-MS/MS method for the analysis of
MESNA in plasma. The method showcases an excellent limit of detection of 20 nM with
excellent linearity (R2 = 0.999 and overall %RA > 90), and a wide linear range (0.05‒200
μM). The method also produced very good accuracy and precision (100±10% and <10%
relative standard deviation, respectively). The validated method was successfully used to
analyze MESNA from treated animals and will enhance pharmacological and therapeutic
research on this promising antidote.
Lastly, sulfur mustard (SM) is a toxic bifunctional alkylating warfare agent, which
causes severe damage to skin, eyes, and respiratory tract. However, there is no antidote for
treating sulfur mustard poisoning and treatment is limited to either washing the affected
area with soap and water or supportive care in cases of inhalation exposure. In recent
research, methimazole (METH), an antithyroid drug has proven to be an effective
nucleophilic scavenger to combat the toxic effects of sulfur mustard analog, 2-Chloroethyl
ethyl sulfide (CEES) but there are no studies on the underlying mechanism of the
scavenging ability of methimazole for CEES in preventing cell death. In this study, we
investigated the interaction between methimazole and CEES for a possible formation of
the novel compound, 2-(2-(ethylthio)ethylthio)-1-methyl-1H-imidazole (ETTMI). The
production of ETTMI from the reaction of CEES with methimazole was proven by the

xvii

detection of ETTMI from CEES-methimazole cell lines. An HPLC-MS/MS method was
developed to analyze ETTMI from HaCat cell lines and media. Using this method, we
showed that ETTMI is produced from the interaction of CEES with methimazole and the
formation of ETTMI could be one of the underlying pathways for the scavenging ability of
methimazole for CEES.
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Chapter 1. Introduction
1.1. Overall Significance
Toxic inhaled agents (TIAs) such as methyl isocyanate, sulfur mustard and cyanide
are used widely in the electronics, chemical, welding, electroplating industries, etc. due to
their great importance. The chemical and electroplating industries process large quantities
of cyanide in the manufacture of solvents, fertilizers, fumigants, plastics, and the myriad
of requirements of modern society. Methyl isocyanate is used in the polyurethane industries
to produce synthetic rubber, adhesives, pesticides, and herbicide intermediates. Despite the
advantages of these TIAs, they can pose serious risks to humans and the environment upon
exposure. It is therefore crucial to develop analytical methods for TIA metabolites and
therapeutic agents to confirm human exposure to TIAs, provide diagnosis and to develop
effective therapeutic agents to combat their toxic effects.
1.2. Project Objectives
This research work addresses three main objectives: 1) Identify a methyl
isocyanate-adduct produced from the interaction of methyl isocyanate (MIC) with tyrosine
and develop and an analytical method for its analysis, 2) Develop a simple and rapid
technique for the analysis of sodium 2-mercaptoethane sulfonate in plasma, and 3) Identify
the reaction product formed from the reaction of sulfur mustard analog, CEES and
methimazole. Chapter 2 describes the reaction of MIC with tyrosine to produce a novel
MIC biomarker, phenyl methyl carbamate utilizing base hydrolysis. Chapter 3 details the
analysis of sodium 2-mercaptoethane sulfonate in plasma using high-performance liquid
chromatography tandem mass-spectrometry. Chapter 4 focuses on the formation of 2-(2(ethylthio)ethylthio)-1-methyl-1H-imidazole(ETTMI) from the reaction of CEES with
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methimazole and analysis of the compound from cell lines. Chapter 5 contains the
conclusion, broader impacts and proposed future works.
1.3. Toxic Inhaled Agents
Inhalation of gases, vapors and aerosols can cause a wide range of adverse health
effects, varying from simple irritation to systemic disease. The large number of chemicals
and complex mixtures present in the environment, such as oxidizing, electrophilic, acidic,
or basic gases, is an area of growing concern for human health.(1, 2) Toxic inhaled agents
(TIAs) are noxious gases and vapors that are harmful and often deadly when inhaled.
Examples include cyanide, methyl isocyanate, sulfur mustard, methyl mercaptan, and
hydrogen sulfide. Due to industrialization and vast growth in the human population, these
TIAs are used extensively for several purposes.(2) Many TIAs are important reactants in
metallurgy and in the organic synthesis of plastics, pharmaceuticals, semiconductors, and
other materials. For example, large amounts of chlorine gas and other TIAs are used for
bleaching and chemical synthesis, and large quantities of ammonia and nitric acid are used
for fertilizer production.(3, 4) Also, cyanide is used in gold mining, electroplating, for the
production of fertilizers, etc.(5) and methyl isocyanate is also used to produce pesticides,
plastics, rubbers, and adhesive. (6)
Large volumes of TIAs are often transported and stored, sometimes near large
population centers to maintain a supply for their use. Unfortunately, accidental leaks from
industrial facilities and transportation vehicles do increase the risk of exposure to both
civilians and industrial workers.(7-9) The Bhopal incident, where a total of 200,000 in a city
of 800,000, in 1984(10) were exposed to the MIC is an example of a major industrial disaster
caused by a leakage in an MIC tank stored by a carbide industry in India.(7, 11) Sulfur
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mustard, chlorine gas, cyanide, etc., have also been used as chemical warfare agents by
many military and terrorist groups to kill and injure civilian population.(12-15)
Exposure to TIAs can cause a spectrum of adverse health effects that range from
subclinical to immediately lethal.(16) Most TIAs are reactive chemical gases (e.g. MIC) and
vapors that can severely change the structures of the proteins, lipids, DNA, and other
biomolecules, resulting in a loss of protein function, DNA mutations, and necrosis of
airway epithelial cells.(17,

18)

TIAs such as sulfur mustard also targets and depletes

sulfhydryl-containing proteins, such as glutathione (GSH), which plays a major role in
maintaining a redox homeostasis in the tissues. This depletion leads to oxidative stress and
other oxidative cellular damage.(19) CN can compromise the oxygen carrying capacity of
blood, as well as the ability of peripheral tissues to utilize oxygen in aerobic metabolism.(2022)

Trace level exposure to reactive TIAs induces irritation, sneezing, coughing, mucus

secretion, tearing, and upper airway inflammation(23) and in severe prolong exposure,
causes severe lung damage. Long-term exposure also damages the delicate alveolar sacs
by reacting with the lung tissues and may even lead to death in some cases.(24, 25)
1.4. Sulfur Mustard
1.4.1. Exposure to sulfur mustard
Sulfur mustard (bis-(2-chloroethyl) sulphide, SM) is a well-known chemical
warfare agent. It is very oily and hydrophobic in nature. Hence, it easily penetrates
membranes and fatty tissues in living systems and stays in soils and other environmental
materials for weeks.(26, 27) Sulfur mustard gas was first synthesized in 1822 by Despretz
and 1860 by Niemann and Guthrie during the studies of interactions between olefins and
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sulfur halogen compounds.(28, 29) Both investigators noticed the typical vesicant properties
of the agent.
The first use of SM was by the Germans during the Battle of Flanders, Belgium in
1917 during World War I.(30, 31) Since its first use, SM has been deployed in several combat
situations, such as United Kingdom against the Red Army (1919), Spain in Morocco (19211927), Italy in Libya (1930), Soviet Union against Japan (1930), Italy against Abyssinia
(1935- 1940), Poland against Germany, Germany against Soviet Union and Poland, Japan
against China during Second World War, and Egypt against Yemen (1963-1967).(32, 33)
During the Iran/Iraq conflict, SM caused more than 100,000 Iranian casualties.(34)
1.4.2. Toxicity of sulfur mustard
The usual routes of entry of SM are the skin, respiratory tract, and eyes, or through
the gastrointestinal tract if SM-contaminated food is consumed.(35) The high lipophilicity
of SM allows it to rapidly penetrate through the hair follicles and sweat glands of skin and
mucous membranes.(36) It has been found that 80% of SM applied to human skin evaporates
and the remaining 20% penetrate the skin.(26) Out of the 20% that penetrates only 10–20%
are fixed to macromolecules in skin.(37) The remaining 80–90% are rapidly transported
away by circulation and distributed among various tissues.(38) Consequently, SM can cause
severe systemic intoxication along with its pronounced local damage.(39)
Exposure to SM could cause several effects. Medical effects of exposure in humans
include ocular and dermal injury, respiratory tract damage, reproductive and
developmental toxicity, gastrointestinal effects, hematological effects, and cancer.(40) The
first contact to SM is mostly painless and only a garlic or sulfur odor can be noticed.
Typically, a symptom-free period is observed for several hours.(41) The duration of this
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period is inversely proportional to the absorbed dose of the agent with the maximum
intensity of symptoms occurring after days.(41) Although the acute effects of SM exposure
are usually delayed, occasional cases of nausea, vomiting, and eye irritation have been
reported, and contact with very high doses may lead to convulsions and coma within this
period.(42) Within 2–6 hours of exposure, typical signs are nausea, fatigue, headache,
painful eye inflammation with photophobia, reddening of face and neck, soreness of throat,
and increased respiratory rate. These symptoms become more severe during the subsequent
6–24-hour period, with skin inflammation and blistering.(32) The blistering becomes more
marked after the 24 hours and there is productive coughing with pus. Anemia may become
apparent after 4–5 days, indicating bone marrow dysfunction.(43, 44). In severe cases, death
is probable after a delay of days or weeks and, in less severe cases, the burns heal slowly.(45)
1.4.3. Mechanism of action of sulfur mustard
The most presently accepted theory of the basis of toxic effects by the SM proposes
that these are consequences of alkylation reactions with cell constituents, mainly with
DNA, but also RNA, proteins, and lipid membranes.(46, 47) These reactions may result in
physiological, metabolic, and genetic failure of cellular functions.
Each 2-chloroethyl side chain of the SM molecule undergoes intramolecular
cyclization with the release of the chloride ion.(33) It has been suggested that the ethylene
sulfonium cation intermediate opens to form the highly reactive carbonium ion which
reacts immediately with nucleophiles, such as DNA, RNA, proteins, and other
molecules.(40) Although the full mechanism behind sulfur mustard toxicity is still not
known due to the number of pathways it can affect, the most characterized mechanism
within living systems is the alkylation of DNA.(48) Almost all bases of DNA are susceptible
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to alkylation, but the N7 position of guanine is particularly important as it is the most
negative site within DNA bases.[82] DNA damage can activate poly (ADP-ribose)
polymerase (PARP) and other repair enzymes. Over-activation or higher levels of PARP
can lead to apoptotic or necrotic cell death.(49)
SM also reacts with glutathione. Depleted intracellular glutathione favors the
production of endogenously produced oxygen species resulting in subsequent peroxidation
of membrane lipids and other oxidative cellular damage.(48)

Figure 1. 1 Formation of episulfonium ion as a result of intramolecular cyclization.

1.4.4. Metabolism of sulfur mustard
As a bifunctional alkylating agent, SM reacts rapidly with various nucleophiles
(e.g., water, glutathione, DNA, and proteins) under physiological conditions via the
intermediate episulfonium ion. Based on these interactions, four major metabolic routes
have been identified in animal models (e.g., rat and mouse).(50, 51) The first metabolism
pathway involves the direct oxidation product of SM, bis-β-chloroethyl sulfoxide (SMO),
the directly hydrolyzed metabolite thiodiglycol (TDG), and its oxidation product
thiodiglycol sulfoxide (TDGO).(52) The second pathway involves a reaction with abundant
glutathione and further oxidation to the sulfone followed by β-lyase cleavage. This leads
to the formation of 1,1’ -sulfonylbis[2-S- (N-acetylcysteinyl) ethane] (SBSNAE), 1,1’ sulfonylbis[2-(methylthio)

ethane]

(SBMTE),

1-methylsulfinyl-2-[2-
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(methylthio)ethylsulfonyl]ethane (MSMTESE) and 1,1-sulfonylbis [2-(methylsulfinyl)
ethane] (SBMSE).(53) The third is the reaction on the critical nucleophilic sites in DNA to
produce SM-DNA adducts.(54) The major sites of DNA alkylation by SM include N7, O6
positions of guanine, N3 position of adenine, and interstrand or intrastrand crosslinks at
the N7 position of guanine. The last route involves reaction with various amino acid
residues present in proteins to form major adducts like HETE-valine adduct of hemoglobin
and an HETE-cysteine adduct of albumin.(49)
1.4.5. Treatments and countermeasures for sulfur mustard poisoning
There is no specific antidote against SM intoxication and also no pretreatment is
available to avoid SM injuries. Several hypotheses have been proposed for SM toxicity and
various treatments have been evaluated.(55) Countermeasures and treatments available are
limited to symptom management and medical therapy. A more recent countermeasure is
scavenger therapy with lots of ongoing research. Medical management involves rapid
decontamination with large amounts of soap and water, followed by supportive care that
may include fluids, respiratory support, analgesia, infection prevention, and basic burn
dressings. Larger blisters (> 2 cm) may heal faster if lanced and debrided.(56) For SM
victims with severe respiratory problems, endotracheal intubation should be considered.(57)
For severe skin and eye damage, skin grafts and transplantation (i.e., corneal
transplantation) may be necessary if chronic effects arise.(57)

1.4.5.1. Proposed and tested therapies.
A more researched area of therapeutics for SM poisoning includes biotherapy and
transplantation. In biotherapy, biological products such as proteins and polysaccharides are
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used to treat sulfur mustard exposure. Proteins like cytokines are used to induce
proliferation and enhance wound healing and protease inhibitors to prevent sulfur
mustard’s vesicating effects.

(58)

Transplantation as a therapy also includes mesenchymal

stem cell (MSC) transplantation to counteract pulmonary disorders, bone marrow
transplantation to alleviate bone marrow suppression, and amniotic membrane (AM)
transplantation to treat corneal damage.(59,

60)

Nonetheless, many of these proposed

therapies have several disadvantages like unwanted toxic effects, counterproductive
biological impacts, and sometimes ineffectiveness in serious cases.
1.4.5.2. Scavenger therapy
In a scavenger therapy, a biologically safe compound is administered to react with
sulfur mustard. The molecule should have high affinity for sulfur mustard (e.g., highly
nucleophilic molecules). Hypothetically, this compound if given right away could help
reduce the direct damage caused by sulfur mustard poisoning and in effect could provide a
different route of sulfur mustard neutralization.(61) Keeping enough level of this scavenger
in either locally affected tissues or systemically would scavenge sulfur mustard to produce
a sulfur mustard-scavenger adduct, which may be excreted as waste or metabolized.
1.4.5.3. Tested Scavengers
Not much research exist that explore the possibility of using a scavenging model
as a post-sulfur mustard exposure counteract method. Among the few, the most promising
molecules that have been explored so far include N-acetyl cysteine (NAC), glutathione,
and 2,6-dithiopurine.(62) NAC and glutathione were tested due to their known antioxidant
properties, biological prevalence, and potential scavenging ability. Although NAC and
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glutathione offered some relief from sulfur mustard toxicity, several studies concluded
their mechanism of action proceeds through pathways disparate to scavenging.(63)
2,6-dithiopurine was chosen as a sulfur-containing thiopurine analog to the
nitrogenous bases in DNA that are known to create adducts with sulfur mustard. Though
this molecule was fairly successful in lessening mutagenesis and other effects involved
with sulfur mustard exposure, it was neglected as a potential therapeutic around 2012.(64)
Recently, methimazole, an antithyroid drug, has proven to be very effective in preventing
apoptosis in CEES-affected cell lines. However, research is still ongoing to validate and
understand the scavenging ability of this potential antidote.
1.5. Methyl isocyanate
1.5.1. Exposure to Methyl isocyanate
Methyl isocyanate (MIC) is a colorless liquid that has a strong odor (with an odor
threshold of 2.1 ppm), a vapor pressure of 348 mm Hg at 20° C, and is highly flammable.(65)
It is the smallest most reactive, and most toxic member of the isocyanate family.(66)
Exposure to MIC usually occurs through inhalation or dermal contact(67) and the sources
of exposure could be either occupational, industrial or accidental.(68) MIC is used
extensively in the carbamate industry as a chemical intermediate in the production of
carbamate insecticides and herbicides. It is also used in the production of polyurethane
rubber, plastics, adhesives, lacquers, paints, etc. Occupational exposure could occur for
individuals who use MIC containing products in their field of work. For example, farmers
who use pesticides like aldicarb and carbofuran are at risk of being exposed.(69, 70) Recently,
MIC has been found as a component of cigarette smoke (about 4 µg per cigarette), putting
primary and second-hand smokers at risk.(71) One type of exposure which civilians may be
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vulnerable to is accidental exposure. In 1984, one of the world’s worst industrial disasters
occurred because of an MIC gas leak in Bhopal, India. During the accidental exposure, an
acute inhalation exposure to the gas, estimated at 13 to 100 ppm, resulted in the deaths of
more than 3,000 people within 5 days and adverse health effects in greater than 170,000
survivors. Within 2-3 hours, about 2,00,000 people were exposed.(72, 73)
MIC is considered to have poor warning properties.

(74)

At 2 ppm, no odor is

detected but subjects may experience eye, nose, and throat irritation and lachrymation. At
4 ppm, symptoms of irritation are more noticeable and exposure is unbearable at 21 ppm.
(75, 76)

1.5.2. Metabolism of Methyl isocyanate
The metabolism of MIC is dictated by its high reactivity in biological molecules.
MIC spontaneously reacts with proteins under physiological conditions.(77) The sites on a
protein molecule where binding of methyl isocyanate may take place are N-terminal amino
group and sidechains of the following amino acids: lysine (primary amine), cysteine (thiol),
histidine (secondary amine in the imidazolyl ring), tyrosine, and serine (hydroxyl).
Therefore, biomonitoring of MIC is achieved by analysis of adducts formed between MIC
and biological molecules.(78) MIC mainly carbamylates the N-terminal amino groups of
proteins. MIC was shown to produce N-methylcarbamoyl adduct at the N-terminal valine
of globin in vitro and in vivo.(79) The adduct is converted using Edman degradation to
produce 3-methyl-5-isopropylhydantoin (MIH), which is used as a biomarker to confirm
MIC exposure.
The presence of high concentrations of glutathione (GSH) in lung endothelial fluid
indicates that inhaled MIC may react chemically with this thiol to form the corresponding
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glutathione conjugate, S-(N-methylcarbamoyl) glutathione (SMG). This was confirmed in
preliminary in vivo studies. When rats were given MIC by intraperitoneal injection, SMG
was excreted as a metabolite in bile.(80) Hence, the major urinary metabolite of MIC is Nacetyl-S-(N-methylcarbamoyl) cysteine (AMCC), a degradation product of the MIC–Sconjugate with

glutathione.(81,

82)

Under physiological

conditions,

the S-(N-

methylcarbamoyl) conjugates are reversible, transferring the MIC moiety to other
nucleophilic groups to produce more stable adducts.(83)
1.5.3. Toxicity and Mechanism of Action of Methyl Isocyanate
The high chemical reactivity of MIC is central to its toxicity as well as commercial
uses. Since the toxicity of isocyanates is directly related to their volatility and vapor
pressure,[93] the smaller the isocyanate molecule, the greater its toxicity.(84, 85) This makes
MIC the most toxic of all isocyanates.(86) MIC has both irritant and pulmonary effects. Its
direct irritant effect on lungs, eyes, skin, secondary to pulmonary toxicity, allergic
response, and nonpulmonary direct effects may contribute to its high toxicity. These effects
are instantaneous and proceed even after a lag period of hours.(76) Usually, the early effects
of acute gaseous exposure to methyl isocyanate are respiratory tract and mucous membrane
irritation. With eye exposure, the victim can have intense burning of the eyes, photophobia,
blepharospasm, profuse lacrimation, lid edema, and superficial corneal ulceration with a
resulting reversible blindness(87) In general, deaths following exposure to MIC occur 1 to
2 days later and a second phase of mortality follows after a week or longer.(88-90)
Based on known reactions, MIC could plausibly cause injury to exposed tissues by
either or both of two mechanisms. The first is through direct addition reactions with tissue
macromolecules and the second is simple physical injury by the heat liberated during
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hydrolysis.(91) For direct addition reaction with tissue macromolecules, MIC and other
isocyanates will carbamoylate hydroxyl groups, sulfhydryls, and imidazoles under
physiological conditions and, at higher pHs, amines will also react with MIC.(77) The
modification of these functional groups by MIC has been shown to inhibit certain enzyme
activities in vitro, and moreover, isocyanates have for years been used as molecular site
probes in the study of enzyme mechanisms.(92) In aqueous systems, the reactions of MIC
with functional groups compete with the hydrolysis reaction. This is a highly exothermic
reaction, and thus the second potential mechanism of tissue destruction is simple physical
injury by the heat liberated during hydrolysis.(91) Nonetheless, the mechanism(s) by which
MIC causes injuries to organs remote from the primary site of exposure still remains
unclear and is paradoxical when one considers the chemical reactivity of this isocyanate,
whose half-life in aqueous media is estimated to be about 2 min.(93) Following inhalation
of MIC vapor, one would expect that the isocyanate would undergo rapid hydrolysis and
fail to cross the alveolar-blood barrier as the complete species. Yet, two inhalation studies
in rats exposed to 14C-labeled MIC showed that radioactivity was distributed rapidly and
extensively throughout the systemic circulation, with the appearance of MIC-derived
radioactivity in urine, bile, and tissue proteins shortly after exposure.(93, 94) Based on these
observations, it was concluded that MIC may be converted in vivo to a “transport” form,
perhaps by reaction with the sulfhydryl groups of either hemoglobin or glutathione (GSH)
to yield carbamate thioester adducts which could revert spontaneously to free MIC at
distant sites.(77, 94) Other toxic effects of MIC include sensory irritation(95, 96) reproductive
toxicity,(86) ocular toxicity,(97,

98)

and neurological toxicity.(96,

99)

There is also some

evidence indicating teratogenic and carcinogenic effects of MIC.(8, 100-102)
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1.6. 2-Mercaptoethane Sulfonate Sodium as a therapeutic for MIC and Sulfur
Mustard exposure.
1.6.1. Uses of MESNA
MESNA, the sodium salt of 2-mercaptoethane sulfonate is a thiol-containing drug
and uroprotectant. It is given adjuvant, orally or intravenously with ifosfamide and
cyclophosphamide orally due to its ability to increase the levels of free thiol groups in the
urinary tract.(103-106) It is also an antioxidant used particularly in renal protection and
reduces the size of urinary bladder cancer. Numerous studies have shown that MESNA has
beneficial effects in ischemic acute renal failure where it scavenges reactive oxygen species
(ROS), due to the presence of the thiol group.(107, 108) Recent studies indicate that numerous
disorders originate from free radical attacks on biological macromolecules such as proteins,
lipids and DNA and an effective antioxidant is crucial in combating these free radical
effects.(109) Coupled with the above, MESNA was proved to be effective in preventing
hemorrhagic cystitis induced by high doses of several chemotherapeutic regimens such as
cyclophosphamide and ifosfamide. Moreover, recent studies have suggested that it is also
effective in reducing intestinal inflammation in colitis.(110) Liu et al.(111) utilized MESNA
as a scavenger of sulfur mustard derivatives, such as 2-chlorethyl ethyl sulfide (CEES) and
2-chlorethyl methyl sulfide scavenger, in a cell-free system. Its efficiency against sulfur
mustard in vitro as well as in vivo was also shown by Jost et al.(112)
1.6.2. Mechanism of action of MESNA
MESNA is mainly used to inactivate acrolein, the toxic metabolite of anticancer
drugs, ifosfamide and cyclophosphamide. Acrolein concentrates in the bladder and causes
cell death by upregulation of reactive oxygen species (ROS).(113) It also activates inducible
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nitric oxide synthase (iNOS) which leads to production of nitric oxide (NO). Both ROS
and NO produce products which are detrimental to lipids, proteins, and DNA.(114)
Furthermore, acrolein may also lead to ulceration of the bladder urothelium. MESNA
protects against effects by binding to the toxic metabolites of these drugs.(115)
Following oral or intravenous administration, MESNA is quickly reduced to
diMESNA in the plasma.(104) Just a small portion of the dose remains in the circulation as
the physiologically active compound. MESNA and diMESNA are both very hydrophilic,
hence they remain in the intravascular compartment where they are rapidly cleared by the
kidneys.(116) About one-third of the diMESNA is converted back to MESNA in the renal
tubular epithelium by glutathione reductase enzymes. The free sulfhydryl groups of
MESNA then react directly with the double bond of acrolein or with urotoxic
4-hydroxyoxazaphosphorine metabolites to form stable and nontoxic compounds which
are excreted in the urine of patients undergoing the MESNA therapy.(117, 118) Because
urinary MESNA excretion greatly exceeds plasma MESNA concentrations, regional
detoxification of ifosfamide in the urinary system occurs.(119, 120) The non-urinary toxic
effects of ifosfamide are not reduced by concomitant MESNA and, importantly, MESNA
does not interfere with the cytotoxic activity of ifosfamide.(121)
1.6.3. Metabolism and pharmacokinetics of MESNA
The main metabolite of MESNA is diMESNA. Early studies have shown that
MESNA is metabolized in vivo to its dimer, diMESNA by a complete spontaneous metal
catalyzed oxidation..(122, 123) Likewise, MESNA can also bind through a disulfide linkage
to low-molecular weight endogenous thiols like cysteine (Cys), glutathione (GSH),
homocysteine (Hcy), an cysteinyl-glycine.(107) MESNA is also moderately protein-bound,
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the bulk of which binds covalently through a disulfide with the single non-intramolecular
disulfide forming cysteine residue of albumin known as Cys34. This thereby displaces
endogenous thiols.(19,

124)

The disulfide binding of MESNA moieties in the oxidative

environment of the plasma is believed to be responsible for MESNA’s inability to
inactivate circulating chemotherapeutics which is very important in cancer treatment.(118)
1.6.4. Toxicity of MESNA
MESNA has been found to have very low acute and chronic toxicity in a standard
preclinical toxicity testing in animals including rats, rabbits, and dogs. It has no teratogenic
or mutagenic effects as tested by Ames test.(103, 125)
The low toxicity of MESNA is not only found in animals but also in humans.
However, the main toxic effect associated with the use of MESNA in humans is vomiting
due to its bad taste when given orally. This conundrum could still be overcome by masking
the taste by giving MESNA in pleasantly flavored drinks, e.g., as coca cola or orange
juice.(126) There are a number of other minor side effects associated with MESNA
administration intravenously (IV). Such side effects include diarrhoea, headaches, and limb
pains.(103, 127) Compared to the effects caused by anticancer drugs, the problem of bad taste
with MESNA is generally considered insignificant. Nonetheless, patient non-compliance
may result, especially in homebased therapy. This in effect may result in hemorrhagic
cystitis while a tablet or capsule formulation of MESNA would clearly overcome this
problem. In a recent volunteer studies, IV MESNA doses of 60 mg/kg resulted in diarrhea
or watery stools.(103) Another recorded adverse effect of MESNA is hypersensitivity
reactions, including rash and leukopenia. These have ranged from mild dermatologic
reactions to severe dermatologic reactions, so it requires close monitoring.(128)
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Chapter 2. Identification and Analysis of a Methyl Isocyanate-Adduct for Exposure
Verification
2.1. Introduction
Methyl isocyanate (MIC) is a highly toxic industrial chemical that is used as an
important precursor for the synthesis of carbamate pesticides (aldicarb, methomyl,
carbofuran, etc.) and to produce plastics.

(73, 90, 129-131)

toxic member of the isocyanate family.

(85)

It is the smallest, most volatile and

MIC has a pungent odor and is extremely

irritating to skin and mucous membranes.(84, 90, 132) However, the odor does not adequately
warn of its presence because the human odor threshold for detection of MIC (>2 ppm)(10)
and mucous membrane irritation (>0.4 ppm) are much greater than MIC’s threshold limit
value of 0.02 ppm.(90,

133)

Hence exposure to MIC can occur at toxic levels without

detection of its odor.(90, 133, 134)
The devastating effects of MIC exposure were evidenced in one of the world’s worst
industrial chemical disasters in Bhopal where a total of 200,000 in a city of 800,000 in
1984 were exposed to the gas.(10, 135, 136). The exact human death toll during the accidental
exposure is still unknown; however, it is estimated that about 5,000 people died within 2
days,(135, 137) and the death toll eventually increased to about 20,000.
Due to the high reactivity of MIC, it easily and spontaneously reacts with endogenous
nucleophilic sites (e.g., amine moieties in proteins) under physiological conditions.(138, 139)
As such, direct analysis of MIC to confirm exposure is not possible. MIC specifically
carbamylates the N-terminal valine of hemoglobin,(140-142) and can react with other amino
acids under physiological conditions including the sulfhydryl group of cysteine,(143, 144) the
hydroxyl groups of tyrosine(77,

145)

and especially serine,(145,

146)

the o-amino group of

lysine,(82, 147) and the imidazole ring of histidine.(148) The reactivity and high vapor pressure
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of MIC cause it to be highly toxic. Exposure to MIC can cause several detrimental effects.
It can affect the respiratory tract, skin, and eyes, and seriously damage the lungs. Chronic
exposure to MIC is known to cause chronic respiratory symptoms like asthma, rhinitis and
hypersensitivity pneumonitis.(7, 11, 90, 149-152) Recent research has also shown that MIC could
be a potential carcinogen. A study conducted by Pesatori et al.(153) observed twofold excess
lung cancer risk in Florida pesticide applicators exposed to carbamate insecticides.
Because MIC reacts strongly with proteins, formation of stable protein adducts offers
the possibility for biomonitoring exposure to MIC. Table 1 lists methods for biomonitoring
of MIC exposure via analysis of protein adducts. Two major strategies have been employed
for analysis of MIC-protein adducts: 1) enzymatic hydrolysis of carbamylated protein
adduct and 2) Edman degradation. Protein enzyme hydrolysis is achieved by addition of
pronase to globin samples, 24-hr incubation, filtration, and analysis by LC-MS/MS. Aside
from enzymatic protein digestion, the main method for confirming exposure to MIC is acid
hydrolysis (i.e., Edman degradation) of MIC adducts of hemoglobin to form methyl
isopropyl hydantoin (MIH). MIH is formed via hydrolysis of the N-terminal valine adduct
of MIC resulting in N-(methylcarbamoyl)valine and subsequent cyclization to form MIH.
The MIH is typically extracted via by liquid-liquid extraction and analyzed using gas
chromatography (GC) or liquid chromatography (LC) with mass spectrometry (MS). Mráz
et al.(154) reported a simplified sample preparation method for analysis of MIH, but the
method involved 20 steps and approximately 9 h which was still lengthy, used up
considerable amounts of energy and generated a large amount of organic waste. In another
method reported by Wang et al.,(155) they utilized a 96-well protein precipitation and
phospholipid removal plate with similar hydrolysis and MIH formation steps. However, a

18

sorbent plate was used to isolate the MIH for UHPLC-MS-MS analysis instead of liquidliquid extraction. This method was rapid, yet it still required many steps (i.e., 18) and
specialized equipment for the sample preparation. Recently, a similar rapid, greener, and
simpler GC–MS method for analysis of MIH isolated from N-methyl carbamoylated
hemoglobin was reported by Logue et al.(130) but the method still required 14 steps and
approximately 5 hours to analyze MIC-exposed samples. Because each of the methods
listed in Table 2.1. has major disadvantages, there is a need to develop a simpler and less
cumbersome sample preparation method for the analysis of protein adducts of MIC to
verify exposure to MIC. The objective of the current study was to develop a simple method
to detect MIC-tyrosine adducts utilizing strong base hydrolysis and subsequent liquid
chromatography tandem mass spectrometry analysis.
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Table 2. 1 Comparison of methods for analysis of MIC-protein adducts.
Analyte

Protein
Reference
Year
Analysis
Approximat Steps
degradation
technique
e time (hr)
MIH
Edman
Mráz et
2002
EI-GC/MS
9
20
(154)
degradation
al.
MIH
Edman
Logue et
2018
EI-GC/MS
5
14
(130)
degradation
al
MIH
Edman
Wang et
2014
HPLC7
18
(155)
degradation
al.
MS/MS
MIC-Hb
Enzymatic
Mráz et
2004
HPLC24.5
5
(144)
adducts
hydrolysis
al.
MS/MS
MLU
Enzymatic
Mráz et
2006
HPLC24.5
5
hydrolysis
al.(143)
MS/MS
MVU
Enzymatic
Mráz et
2006
HPLC24.5
5
(143)
hydrolysis
al.
MS/MS
PMC
Base
Current
2021
HPLC4
12
hydrolysis
method
MS/MS
NR = not reported
MLU = (N-methylcarbamoyl) lysine
MVU = N-methylcarbamoylvaline (MVU)
EI-GC-MS = electron impact ionization- gas chromatography- mass spectrometry
HPLC-MS/MS = high performance liquid chromatography- tandem mass spectrometry

LOD

R2

Precision

0.031
mg/kg
0.05
mg/kg
1.6
mg/kg
NR

NR

< 10%

0.993

< 4.5%

0.999

< 1.7%

100 ±
5.7
NR

NR

NR

NR

0.990

NR

NR

0.990

NR

NR

0.998

< 10%

100 ± 9

1.015
mg/kg
0.87
mg/kg
0.02
mg/kg

Accurac
y
NR
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2.2. Materials and Methods
2.2.1. Materials
All reagents and solvents were at least HPLC grade, unless otherwise stated. Formic
acid, acetonitrile, hydrochloric acid (certified ACS), acetone, amino acids (tyrosine, serine,
lysine, histidine, and valine) and chloroform were purchased from Fisher Scientific (Fair
Lawn, NJ, USA). Sodium hydroxide, phenol and N-methylimidazole were obtained from
Sigma-Aldrich (St. Louis, MO). Water used for this study was purified by reverse osmosis
and filtered through a Lab Pro polishing unit from Labconco (Kansas City, KS, USA).
Methyl isocyanate (MIC) was synthesized for the analytical work in our lab by the method
of Kaushik et al. (130) and Logue et al.(130, 156) based on Curtius Rearrangement method. The
MIC was collected via distillation and the purity was confirmed using 1H NMR at 95%.
MIC for animal inhalation exposures was synthesized by MRIGlobal (Kansas City, MO)
through the Curtius Rearrangement method. Purity of this MIC was >99.5% as measured
by gas chromatography-flame ionization detection. Phenyl methyl carbamate (PMC) and
its internal standard (PMC-D5) were synthesized in our lab as discussed below. All stock
solutions were stored at -30 °C. Working PMC and PMC-D5 solutions were obtained from
stock solutions of PMC (1 mM) or PMC-D5 (1 mM) via serial dilutions to the desired
concentration.
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Figure 2. 1 Scheme for the synthesis of PMC from the reaction of phenol with MIC in
acetonitrile (ACN) via Lossen rearrangement using N-methylimidazole (NMI) as a
catalyst.(157)

2.2. Synthesis of PMC and PMC-D5
The reaction scheme for the synthesis of PMC is shown in Figure 2.1. The synthesis
of PMC and its internal standard were achieved by Lossen’s rearrangement modification
of the Yoganathan et al.(157) method for the one pot synthesis of carbamates. Briefly, phenol
(0.941 g, 2 eq) and N-methylimidazole (NMI, catalyst) (0.034 g, 0.1 eq) were dissolved in
50 mL acetonitrile with stirring. MIC (2.94 mL, 1 eq) was added dropwise at 23 °C with
continuous stirring for 3 hrs. The reaction mixture was left overnight at room temperature
and concentrated on a rotary evaporator until a yellowish-white liquid was formed. Normal
phase column chromatography was performed using an ethyl acetate:hexane (60:40)
mobile phase. Characterization was achieved by 1-H NMR spectroscopy and ESI-MS
operated in positive polarity mode. 1-H NMR (600 MHz, CDCl3): δ 2.89 (d, 3H), 7.12 (d,
2H), 7.19 (t, 1H), 7.35 (t, 2H). ESI (+)-MS: m/z 152.40, 77.0, 95. An isotopically labeled
standard, PMC-D5, was synthesized as described above for PMC, with phenol replaced
with phenol-D5. ESI (+)-MS: m/z 157.10, 82, 100.
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2.2.2 Biological samples
For method development and validation, Sprague-Dawley rat red blood cells
(RBCs) with K2EDTA as anticoagulant, were purchased from Bioreclamation IVT
(Westbury, NY, USA) and immediately stored at −80 °C until used. For this experiment,
male Sprague-Dawley rats (300-350 g) were obtained from Charles River Laboratories and
acclimated at MRIGlobal (AAALAC International accredited) for 5-7 days prior to study,
including acclimation to a nose-only inhalation exposure apparatus 30 minutes daily for 3
days prior to exposure. All procedures were approved by the MRIGlobal Institutional
Animal Care and Use Committee. For evaluation of the usefulness of PMC as a marker of
MIC exposure, rats were exposed to MIC and blood was sampled for PMC analysis. MIC
inhalation exposure was performed as previously described by Logue et al..(6) and Rancourt
et al.(158) Briefly, unanesthetized rats were placed in a flow-directed nose-only inhalation
exposure system (CH Technologies, Westwood, NJ) housed in a fume hood connected to
a proprietary custom MIC vapor diffusion system (MRIGlobal). The gas constituents
delivered through the inner plenum of the exposure system were continuously monitored
by Fourier transform infrared spectroscopy, with adjustments made to the amount of MIC
delivered so as to limit deviation in the height of the absorption peak for MIC in the
atmosphere to less than 1% during the course of exposure. Animals were exposed to 375
or 500 ppm MIC for 30 minutes. After exposure, rats were allowed to recover in their home
cages, and for the duration of study, rats were monitored every 2 hours for peripheral blood
oxygen saturation levels(159), respiratory distress quality, and physical activity score as
previously described Nick et al(159). Upon meeting euthanasia criteria (oxygen saturation
<70%, cumulative clinical distress score >7), rats were anesthetized by IP injection of a
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mixture of ketamine (75 mg/kg), xylazine (7.5 mg/kg), and acepromazine (1.5 mg/kg), and
blood was collected from the abdominal aorta into 3.2% trisodium citrate (1:9
citrate:blood). Red blood cells (RBCs) were fractionated by centrifugation of whole blood
at 3000 x g for 15 minutes at 4°C. Plasma was removed, and aliquots (0.5-1 mL) of packed
RBCs were immediately frozen and stored at -80°C, then shipped on dry ice to South
Dakota State University and stored at -80°C until analysis.
2.2.3 Sample preparation
Protein precipitation was achieved by adapting the method employed by Logue et
al.(130) RBCs (3 mL) were added to a 15-mL centrifuge tube. Acetone with 1% HCl (v/v)
was added to the RBCs with a 3:1 volume ratio of acetone to RBC. The mixture was further
vortexed and centrifuged at 800 × g for 10 min at 20 °C. The supernatant was discarded,
and the precipitate was washed once by adding 6 mL of acetone and breaking the pellet
with a clean spatula. The mixture was vortexed and again centrifuged, as above, and the
supernatant was discarded. The precipitate was dried in a centrifugal evaporator
(Labconco, Kansas City, USA) equipped with a rotary vacuum pump (Edwards,
Glenwillow, USA) at 30 °C until dry. The precipitate was stored at −80 °C until ready for
use. A portion of the RBC protein precipitate (100 mg) was added to a clean 15 mL
centrifuge tube. For base hydrolysis, aqueous NaOH (1mL of 10 M) was added to the
precipitate. The mixture was then vortexed and heated at 70 °C for 2 hr. The sample was
then removed from heat and cooled to room temperature. The PMC-D5 IS (200 µL) was
spiked into the mixture and the resulting solution was vortexed 3-4 times. (Note: For
method development or calibration, PMC standard was spiked with PMC-D5) HCl (1 mL,
18 M) was then added to neutralize the base and chloroform (2.5 mL) was added to extract
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PMC. The resulting mixture was capped, vortexed for about 5 min and centrifuged at 2000
×g for 20 min. Rarely, an emulsion develops in the sample. If an emulsion was visually
apparent, the organic layer was transferred into a new tube and centrifuged again at 2000
×g for 5 min. An aliquot of the organic layer (2 mL) was then transferred into a 4 mL glass
screw-top vial and dried under nitrogen for 30 min at room temperature. The dried samples
were then reconstituted with 500 μL of 80% acetonitrile in water, mixed thoroughly,
filtered with a 0.22-μm tetrafluoropolyethylene syringe filter, and analyzed using
HPLC−MS/MS.
2.2.4 HPLC-MS/MS analysis of PMC
Liquid chromatography analysis was performed on a Shimazu UFLC with LC20ADXR controller. The column used for chromatography was an Agilent polymeric
reversed-phase column, eclipse Plus C18 (3.0 × 100 mm, 1.8 μm, part #:PN 959964-302).
The chromatographic separation was achieved using isocratic elution at a flow rate of 0.2
µL/min at 90% B held for 5 minutes. Mobile phases A and B were 0.1% formic acid in
water and acetonitrile, respectively. The column was equilibrated for 1 min and a volume
of 10 µL was injected for HPLC-MS/MS analysis. For MS analysis, a tandem mass
spectrometer (Sciex Q-Trap 5500 MS) equipped with an electrospray ionization interface
in the positive polarity mode was used to detect PMC and PMC-D5. Optimization of mass
spectrometric conditions was accomplished by direct infusion of a standard solution of
PMC and PMC-D5 into the spectrometer at a flow rate of 10 µL/min. After infusion of
standard solutions of PMC and PMC-D5 into the ESI, molecular ions of m/z 152.40 ([M +
H]+) and m/z 157.10 ([M + H]+ ) respectively, were identified. Multiple reaction monitoring
(MRM) parameters for PMC and PMC-D5 were optimized and are outlined in Table 2.2.
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Nitrogen (50 psi) was used as the curtain and nebulization gas. The ion spray voltage was
4,500 V, the source temperature was 500 °C, and both the nebulizer (GS1) and heater (GS2)
gas pressures were 90 psi. The collision cell was operated with an entrance potential of
10.0 V and an exit potential of 11.0 V at a “medium” collision gas flow rate. The total mass
spectrometry acquisition time was 5 min.
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Table 2. 2 MRM transitions, optimized collision energies (CEs), cell exit potentials (CXPs) and declustering potentials (DPs) for the
detection of PMC and PMC-D5 by MS/MS analysis.
Compounds
PMC (quantification)
PMC (identification)
PMC-D5 (quantification)
PMC-D5 (identification)

Q1 (m/z)
152.40
152.40
157.10
157.10

Q3 (m/z)
95
77
100
82

Time (ms)
100
100
100
100

CE (V)
23.70
38.28
22.00
40.99

CXP(V)
12.88
10.03
45.99
14.12

DP (V)
8.99
39.82
10.35
24.02
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2.2.5 Calibration, quantification, and limit of detection
Validation of the method was achieved by following Food and Drug Administration
guidelines.(160, 161) To determine the limit of detection (LOD), multiple concentrations of
PMC below the LLOQ were analyzed in rat RBC utilizing the sample preparation method
described above (Section 2.2.3.) The lowest concentration which reproducibly produced a
signal-to-noise ratio of at least 3 was determined as the LOD. Calibrators (0.05, 0.1, 0.2,
0.5, 1, 2, 5, 10, 20, 50, 100 and 200 μM) and quality-control (QC) standards (0.3, 3, and
30 μM) were prepared from a stock solution of PMC in 80% acetonitrile:water. Aliquots
(200 µL each) of PMC and PMC-D5 were spiked into rat RBC precipitate to create
calibration standards utilizing the sample preparation method described above. Qualitycontrol (QC) standards (0.3, 3, and 30 μM) were also prepared from the same stock
solution. The QC standards were not included in the calibration curve. Each calibration
standard was prepared in triplicate and QC standards in quintuplicate. After analysis of the
calibration standards, calibration curves were plotted using the average signal ratios of
PMC and PMC-D5 as a function of PMC concentration. Weighted (1/x2) and unweighted
calibration curves were created using linear least squares. A weighted 1/x2 fit was chosen
as the best model to fit the calibration data. The LLOQ and upper limit of quantification
(ULOQ) were established using the inclusion criteria of <15% relative standard deviation
(%RSD, as a measure of precision) and a percent error (as a measure of accuracy) of
100±15%. The percent error was calculated based on the comparison of the PMC
concentration back-calculated from the calibration curve to the nominal PMC
concentration of the QC standard. The percent residual accuracy (PRA) was used to
determine the goodness of-fit of the calibration curves (i.e., PRA values ≥90% are
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indicative of a good fit).(162) Intraassay precision and accuracy were calculated from each
day, and interassay precision and accuracy were calculated by comparing the data gathered
over three separate days.
2.2.6 Recovery and matrix effect
The recovery of PMC was determined by the analyzing five QC replicates (low,
medium, and high concentrations) prepared in aqueous solution compared with equivalent
QCs in rat RBC precipitate. Recovery was defined as the ratio of the average analyte peak
area or signal ratio from spiked rat RBC precipitate which went through the sample
preparation procedure to the average peak area or signal ratio of aqueous QC standards
containing PMC reconstituted in 80% acetonitrile in water, expressed as a percentage.
Calibration curves of PMC from aqueous samples and spiked RBC precipitate were
established to evaluate the matrix effect of the RBC precipitate on the analysis of PMC.
The ratio of calibration curves slopes, RBC-precipitate to aqueous calibration standards,
was used to quantify the matrix effect. A slope ratio (RBC precipitate slope/aqueous slope)
equal to one indicates negligible matrix effect, a slope ratio greater than one indicates an
enhancement effect and slope ratio less than one indicates suppression of the analyte signal
by the RBC precipitate.
2.2.7 Stability
The stabilities of both the PMC and the MIC-protein adduct were evaluated. The
stability of PMC (autosampler, benchtop, and long-term) in RBC precipitate was evaluated
by analyzing low and high QCs stored at various temperatures at multiple storage times.
Autosampler stability was performed by spiking rat RBC precipitate with low and high QC
PMC standards and preparing for analysis. The samples were placed on the auto-sampler
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(at ambient temperature) and analyzed at approximately 0, 1, 2, 4, 8, 12, and 24 h following
preparation. Internal standard was not used for the autosampler stability experiment, as it
would compensate for the loss of PMC during the storage. To evaluate the benchtop
stability of the MIC-protein adduct, MIC was initially spiked in RBCs at concentrations
which produced PMC signals similar to the low and high QCs, 3.4 μmol/g and 85 μmol/g,
respectively. The MIC-spiked rat RBC samples were vortexed for 2 min and shaken
overnight in a Benchmark INCU-SHAKER™ 10-L shaking incubator at 300 rpm and room
temperature. The samples were then stored on the bench top for 0, 1, 2, 4, 8, 12, and 24 h.
They were precipitated, dried, and stored in −80 °C freezer until all samples were ready for
analysis. During analysis, samples were prepared using the sample preparation steps
outlined above and analyzed using the developed HPLC-MS/MS method. For the longterm stability of the MIC-protein adduct, sample preparation was carried out as with the
benchtop stability, except that samples were stored at room temperature, 4 °C, −20 °C and
−80 °C and 4 °C for 0, 1, 2, 5, 15, and 30 days. Samples were then prepared and analyzed
using the developed method.
2.3 Results and Discussion
2.3.1 Mechanism of MIC-tyrosine adduct formation
Previous studies of the reaction of MIC with amino acid residues of common
proteins showed that MIC reacts under physiological conditions at the N-terminal valine
of hemoglobin, the sulfhydryl group of cysteine, the hydroxyl groups of tyrosine and
serine, the Ɛ-amino group of lysine, and the imidazole ring of histidine to form their
respective adducts.(139, 163, 164) Mraz et al.(139) in 2004 detected adducts of MIC-histidine,
MIC-tyrosine, MIC-lysine and MIC-valine when they reacted 100 molar excess of MIC
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with hemoglobin, followed by hydrolysis with pronase HPLC-MS/MS analysis. In this
study, we modeled the interaction of MIC with tyrosine, lysine, histidine, serine, and valine
residues by reacting MIC with these individual amino acids. We then used a simple base
hydrolysis to evaluate the potential for use of resulting hydrolysis products as markers of
MIC-protein adducts. Reaction of MIC with these amino acids and rat hemoglobin and
subsequent base hydrolysis with heating led to the formation of a novel marker of the MICtyrosine adduct, phenyl methyl carbamate (PMC). Figure 2.2 shows the proposed reaction
scheme for the reaction of MIC with tyrosine and subsequent base hydrolysis. In summary,
the hydroxyl group of tyrosine is proposed to react with the electrophilic carbon of methyl
isocyanate to form an MIC-tyrosine adduct which subsequently undergoes base hydrolysis
under heat to cleave the phenyl-carbon bond leading to the formation PMC and a serine
residue as the by-product. Cleavage by base hydrolysis is supported by the proposed SN2
reaction mechanism outlined in figure 2.3.

Serine residue

MIC
tyrosine
MIC-tyrosine adduct

PMC

Figure 2. 2 Reaction pathway for the formation of PMC from the reaction of tyrosine with
MIC. Tyrosine is proposed to react with MIC to form an MIC-tyrosine adduct which
undergoes base hydrolysis to produce phenyl methyl carbamate (PMC).
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Figure 2. 3 Proposed reaction mechanism for the formation of PMC. MIC-Tyrosine adduct
undergoes an SN2 reaction in the presence of strong aqueous NaOH to cleave PMC at the
CH-aromatic bond. R1= CHNH, R2= NHC=O and R3=CH3.
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2.3.2 Phenyl methyl carbamate as a biomarker for MIC exposure.
To confirm the formation of PMC from MIC exposure, analytical methods were
developed to detect and quantify PMC in the hemoglobin isolated from of MIC-exposed
rats. The mass spectra of PMC and PMC-D5 are shown in Figures 2.4A and B respectively,
produced by ESI (+)-MS. The molecular ions (M+H)+, with abundant ions identified
respectively. For PMC, transitions 152.4 → 95 and 152.4 → 77 were used for
quantification and identification, respectively. The quantification and identification
transitions for PMC-D5 were 157.1 → 82 and 157.1 → 100, respectively. The optimized
MS/MS parameters for the detection of PMC and PMC-D5 are shown in Table 2.2.
Figure 2.5. shows the HPLC−MS/MS chromatograms of PMC analyzed from
spiked rat RBC precipitate (Figure 2.5A), MIC-spiked rat RBC precipitate (Figure 2.5B)
and from non-exposed and MIC-exposed rats (Figure 2.5C). PMC was detected from
hemoglobin precipitate of both MIC-spiked rat RBC precipitate and MIC-exposed rats,
eluting at about 2.4 min. The detection of PMC from both MIC-spiked rat RBC and MICexposed rats definitively confirms the formation of PMC from reaction between MIC and
tyrosine under strong base hydrolysis. This supports the reaction scheme shown in Figure
2.2 and provides strong evidence of the in vivo binding of MIC to tyrosine proteins and its
transformation to PMC under strong base hydrolysis.
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Figure 2. 4 ESI (+) product ion mass spectra of PMC (A) and PMC-D5 (B) with
identification of the abundant ions. Molecular ions of PMC and PMC-D5 [M+H] +
correspond to 152.40 and 157.10, respectively. Insets, structures of PMC (A) and PMCD5 (B) with abundant fragments indicated.
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Figure 2. 5 HPLC−MS/MS chromatograms of (A) PMC-spiked rat RBC (B) PMC from
MIC-spiked rat RBC, (C) PMC from RBC of MIC-exposed rat, non-exposed and exposed
are presented.

2.3.3 Detection of serine as a by-product of base hydrolysis of MIC-tyrosine adducts
Base hydrolysis of the product of MIC with tyrosine according to the proposed
reaction scheme (Figure 2.2) should lead to the formation of PMC with a serine residue as
the by-product. To confirm this hypothesis, analysis of serine as a by-product of base
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hydrolysis of the MIC-tyrosine reaction product was attempted. A high-performance liquid
chromatography with fluorescence detection was used to detect serine following Ophthaldialdehyde (OPA) derivatization in the presence of a thiol.(165) To confirm serine as
a by-product, the aqueous layer of a based-hydrolyzed MIC-tyrosine reaction solution was
analyzed for serine. Serine was prominently detected from this solution with excellent
efficiency and selectivity. The detection of serine from the MIC-tyrosine reaction solution
provides strong support for the proposed reaction scheme (Figure 2.2).
2.3.4 HPLC-MS/MS analysis of PMC
The analytical method for PMC presented here involved a simple sample
preparation procedure as compared to existing methods used for analysis of MIC-protein.
The method consists of RBC precipitation, followed by strong base hydrolysis of MICtyrosine adducts from isolated hemoglobin to form PMC, rapid liquid-liquid extraction,
and analysis via liquid chromatography tandem-MS analysis. The overall sample
preparation and HPLC−MS/MS analysis time was approximately 4 hr, which is far shorter
than MIH analysis methods or enzymatic digestion methods for analysis of MIC-protein
adducts (Table 1.1). PMC was fully resolved from other components in the RBC matrix
and showed excellent efficiency with a peak eluting at approximately 2.3 min.
Calibration curves for PMC were constructed within the concentration range
0.05−100 μM. Using the inclusion criteria of 100 ±15% for accuracy and ≤15% for
precision, the 0.05, 0.1 and 100, 200, μM calibrators fell outside the linear range. Therefore,
the linear range was 0.2−50 μM and was best described by a 1/x2 weighted linear regression
producing R2 >0.99 and percent residual accuracy (PRA) of 96.4. The lower limit of
quantification (LLOQ) and upper limit of quantification (ULOQ) were determined to be
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0.2 and 50 µM, respectively. The PRA values of all the calibration curves analyzed were
≥90%, indicating excellent fit of the data over the entire linear range (i.e., PRA values
≥90% are indicative of a good fit). The LOD (signal to noise = 3) was 0.02 mg/kg as
validated by analysis of multiple lower concentrations of PMC-spiked RBC samples over
a 3-day period.
2.3.5 Accuracy and precision
The accuracy and precision of the method were established by quintuplicate
analysis of three QC standards: low, medium, and high (0.3, 3, and 30 μM) on three days
within 7 calendar days (Table 2.2). The precision and accuracy for the method was
excellent over with interassay accuracies and precisions were within 4% of calibrators. The
intraassay accuracies and precisions were also ≤6% and 7% of calibrators, respectively.
Calibration curves were constructed on three different days to determine the repeatability
of the calibration. As shown in Table 2.3, each of the three calibration curves consistently
produced an R2 > 0.999 and consistent slopes over the 3 days (similar % RSD).
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Table 2. 3 Intra and interassay accuracy and precision of PMC produced by base hydrolysis of MIC-tyrosine adduct.
Nominal
concentration
(µM)

Intraassay
accuracy (%)b

Intraassay
precision (%CV)b

Day 1
Day 2
Day 3
Day 1
0.3
100 ± 1.2
100 ± 0.6
100 ± 3.0
3.3
3
100 ± 0.2
100 ± 0.3
100 ± 5.6
3.2
30
100 ± 3.8
100 ± 1.7
100 ± 1.5
2
a
QC method validation (N = 5).
b
Mean of three different days of QC method validation (N = 15)

Day 2
3.3
4.4
5.7

Day 3
6.6
2.8
4.3

Interassay
accuracy
(%)a

Interassay
precision
(%RSD)a

100 ± 1.2
100 ± 0.2
100 ± 3.8

˂ 3.4
˂ 3.2
˂ 2.0

Table 2. 4 Calibration equations and coefficients of determination (R2) for calibration curves created over 3 days.
Day

Calibration Equation

1

2

a

y = 70.353x + 20.039

R
0.9992

PRA
96.7

2

y = 68.883x + 4.683

0.9996

97.6

3

y = 64.753x + 14.395

0.9998

97.2
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2.3.6 Matrix effect and recovery
The matrix effect was assessed by comparing the slopes of standard curves of PMC
in aqueous solution and rat RBC matrix. The value of the slope ratio (RBC matrix
slope/aqueous slope) from the calibration curves was 0.85, indicating approximately about
15% suppression of PMC signals in rat RBC matrix The recoveries for low, medium, and
high QCs were 19.69%, 40.58%, and 41.09%, respectively. The loss of PMC during the
sample preparation steps may be due to incomplete extraction of PMC from the RBC
matrix into the organic layer. Since the % recovery value is the combination of matrix
effect and recovery, the minor matrix effect in rat RBC does slightly contribute to
recoveries <100%. To investigate the ability of the internal standard to correct for poor
recovery, the internal standard was used to correct the signals for the recovery experiment.
This correction drastically Recoveries were improved the results, with low (LQC), medium
(MQC), and high QC (HQC) samples being 96.38%, 90.60% and 91.10% respectively. It
is therefore highly recommended to use internal standard to correct for loss of PMC during
sample preparation and matrix effects.
2.3.7 Stability of PMC and MIC-tyrosine adduct
To determine the stability of PMC spiked into rat RBC in the autosampler, samples
(LQC and HQC) were placed in the autosampler after they went through the sample
preparation steps and were analyzed after 0, 1, 2, 4, 8, 12 and 24 hr. PMC signals for both
LQC and HQC samples were stable for all times tested. We also investigated the stability
of the MIC-tyrosine adduct on the benchtop. This was achieved by spiking MIC directly
onto isolated hemoglobin, shaking and storing on the benchtop. Samples were prepared
and analyzed after 0, 1, 2, 4, 8, 12 and 24 hr of storage. Both LQC and HQC MIC-tyrosine
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adduct were stable for the period tested. For long term stability, MIC-tyrosine adduct was
stored at room temperature, 4 °C, −20 °C and −80 °C. Samples were prepared and analyzed
after 0, 1, 2, 5, 15 and 30 days. At room temperature and 4 °C, samples were stable up to
5 and 15 days, respectively. However, at the lower temperatures (−20 °C and −80 °C),
samples were stable at least 30 days (i.e., the longest time period tested). Based on the
results of the stability studies, we suggest that when storage is necessary for more than 2
weeks, MIC-tyrosine samples should be stored at −20 °C or −80 °C.
3.8 Analysis of PMC from MIC-exposed animals and its correlation with MIC dose
Correlation of PMC to MIC dose or exposure was first assessed by analyzing RBCs
from rats (N = 44) dosed with different concentrations of MIC (i.e., 375 and 500 ppm) and
non-exposed rats (i.e., naïve) to serve as a control group. The developed method for PMC
was used to analyze the samples after preparation. PMC was detected in all groups (Figure
2.6). An analysis of variance with Dunn’s multiple comparison test to determine significant
differences between the groups was performed. Figure 2.6 results shows that there is
significant difference between the different groups analyzed. While the actual inhaled dose
of MIC cannot be conclusively measured, the relationship shown in Fig. 2.6 is very
promising for the potential to use PMC as a biomarker to confirm MIC exposure.

P MC concentration (µM)
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Figure 2. 6 Correlation of MIC dose to concentration of PMC from exposed rats.
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2.4 Conclusion
A novel MIC biomarker, PMC, was discovered based on the interaction between
MIC and tyrosine. Using strong base hydrolysis of tyrosine adducts of MIC, a rapid and
simple HPLC−MS/MS with excellent accuracy and precision was successfully developed.
This method was able to quantify PMC from base hydrolysis of RBCs from rats exposed
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to MIC. The detection of PMC from rats exposed to MIC reveals PMC as a promising
biomarker for verification of MIC exposure.
2.5 Acknowledgements
We gratefully acknowledge support from the CounterACT Program, National
Institutes of Health Office of the Director, and the National Institute of Environmental
Health Sciences (NIEHS), Grant number U54 ES027698 (CWW). The opinions or
assertions contained herein are the private views of the authors and are not to be construed
as official or as reflecting the views of the National Institutes of Health or the CounterACT
Program.

45

Chapter 3. Analysis Of Sodium 2-Mercaptoethane Sulfonate in Rat Plasma Using
High Performance Liquid Chromatography Tandem-Mass Spectrometry
3.1. Introduction
The sodium salt of 2-mercaptoethane sulfonate (MESNA) is a thiol-containing drug
used to combat urothelial toxicity in patients treated with antineoplastic drugs (e.g.,
ifosphamide and cyclophosphamide).(103, 104, 166-168) Specifically, some antineoplastic drugs
produce toxic side products (e.g., acrolein). MESNA interacts with these metabolites to
reduce their toxicity. Because it is important that a chemoprotective agent does not
deactivate the potency of anti-cancer drugs, the inability of both MESNA and diMESNA
(i.e., oxidized form of MESNA) to passively cross biological lipid membranes due to their
hydrophilicity is advantageous since they do not enter cells to disrupt the mechanism of
action of anti-cancer drugs.(103) Other uses of MESNA in the medical field include
prevention of cisplatin-induced nephrotoxicity by locally reacting with cisplatin species in
the kidneys(169-173) and scavenging reactive oxygen species (ROS) due to the ability of its
thiol functional group to act as an antioxidant.(110, 126, 166, 174)
Due to the importance of MESNA in the medical field, several methods have been
developed over the years for its bioanalysis, including colorimetry and high performance
liquid chromatography (HPLC) methods using ultraviolet detection (UV),[17] fluorescence
detection (FLD),[4] and electrochemical detection (ECD).(109) However, each of these
methods has major limitations. Table 1 lists methods for the analysis of MESNA from
biological matrices, along with important analytical characteristics. Ellman in 1959
reported the first analysis of MESNA by non-specific colorimetric assay. However the
method was not selective enough to distinguish between MESNA and endogenous thiols
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in biological samples, such as cysteine.(175) To address this limitation, several HPLC
techniques were developed to more selectively analyze MESNA from biological
samples.(175-179) An HPLC-UV technique using 2-chloro-1-methylquinolinium tetrafluoroborate for precolumn derivatization was reported by Glowacki et al in 2001.(178-180) The
method produced excellent accuracy and precision, but suffered from small linear range.
Moreover, the selectivity of the method for practical use was limited, with other thiol
containing compounds from the biological sample producing similar retention times as
MESNA. Verschraagen et al.(181) developed a micro-HPLC method using dual ECD with
walled-jacked electrodes to selectively analyze MESNA. Although the method worked to
selectively analyze MESNA, the recoveries were poor, the linear range was small, and the
analysis time was lengthy. The method also produced poor sensitivity relative to other
bioanalytical techniques for analysis of MESNA.(167, 182) Mare et al.(166) reported an HPLCFLD method for analysis of MESNA from plasma and tissues but it requires long sample
preparation steps making it inconvenient to analyze large number of samples(166, 183, 184)
Due to the drawbacks of the currently available bioanalytical methods, a highly robust
and sensitive method for the analysis of MESNA in biological samples is needed.
Therefore, the objective of the current study was to develop and validate an HPLC-MS/MS
method to analyze MESNA from rat plasma.
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Table 3. 1 Comparison of bioanalytical methods for analysis of MESNA.
Approximate
sample
preparation and
analysis time
(min)
NR

R2

Precision
(%RSD)

Accuracy
(%)

LOD
(nM)

Linearity
(µM)

NR

NR

NR

NR

NR

NR

0.997

< 3%

100 ± 3

40

0.16-30

HPLC-ECD

45

0.999

< 5%

100 ± 6

NR

3–120

2005

HPLC-FLD

40

0.999

< 10%

100 ± 8.7

1.6

0.0025–2.5

2021

HPLCMS/MS

20

0.999

< 10%

100 ± 10

20

0.05–200

Reference

Year

Analytical
method

Ellman et al(175)

1959

Glowacki et
al.(178)
Verschraagen et
al.(167)
Mare et al.(166)

2001

Ellman’s free
thiol assay
HPLC-UV

2003

Current technique

NR = not reported, HPLC = high performance liquid chromatography, UV = ultraviolet (detection), ECD = electrochemical detection, FLD = fluorescence
detection, MS/MS = tandem mass spectrometry
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3.2. Materials and Methods
3.2.1 Materials
All reagents and solvents were at least HPLC grade, unless otherwise stated.
Ammonium formate was purchased from Sigma-Aldrich (St. Louis, MO, USA). Methanol
and acetone (LC–MS grade) were obtained from Fisher Scientific (HanoverPark, IL, USA).
MESNA (>98% purity) and the internal standard, sodium 3-mercapto-1-propane sulfonate
(3-MPS, >90% purity), were purchased from Sigma-Aldrich (St. Louis, MO, USA). Water
used for this study was purified by reverse osmosis and filtered through a Lab Pro polishing
unit from Labconco (Kansas City, KS, USA). Stock solutions of MESNA and 3-MPS (10
mM) were prepared in water and stored at 4 °C. The stock solutions of MESNA and 3MPS were freshly diluted to desired working solutions in water or plasma immediately
prior to each experiment.
3.2.2. Biological Samples
Plasma from Wister Hannover rats with 3.2% sodium citrate anticoagulant (0.2 µm
filtered), was purchased from BioIVT for the analytical method development and
validation. The plasma was stored at -80 °C until used. To evaluate the ability of the method
to detect MESNA in the plasma of treated animals, plasma samples were obtained from
MESNA-treated male Sprague-Dawley rats. For this experiment, male Sprague-Dawley
rats were obtained from Charles River Laboratories and acclimated at the University of
Colorado Denver-Anschutz Medical Campus (AAALAC International accredited) for at
least 7 days prior to study. All procedures were approved by the UCD-AMC Institutional
Animal Care and Use Committee. A pharmaceutical grade formulation of MESNA (Baxter
Healthcare Corporation, NDC 10019-953-01) was administered to rats at 300 mg/kg by
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intraperitoneal (IP) injection. Control animals received an equivalent volume (3 mL/kg) of
saline (Hospira) containing 0.25 mg/mL EDTA (Sigma 03690) by IP injection. At various
times following treatment (20 min, 1, 3, or 6 hr), rats were anesthetized by IP injection of
a mixture of ketamine (75 mg/kg), xylazine (7.5 mg/kg), and acepromazine (1.5 mg/kg)
for blood collection. Blood was collected from the abdominal aorta into 3.2% trisodium
citrate anticoagulant (1:9 citrate: blood). Plasma was obtained by centrifugation of blood
at 2050 x g for 15 minutes at 4 °C and subsequent transfer of plasma to a clean centrifuge
tube (2 mL). The plasma was then flash frozen in liquid nitrogen and shipped on dry ice
(overnight) to South Dakota State University. Upon receipt, the plasma was stored at -80
°C until analysis was performed.
3.2.3. Sample preparation for HPLC-MS/MS analysis
To plasma samples (150 µL), internal standard (100 µL of 10 µM 3-MPS) was
added and the mixture was vigorously stirred. Acetone (750 µL) was then added to the
plasma to precipitate proteins. The sample was vortexed 3-4 times, and then cold
centrifuged (-5 °C) at 13,000 rpm (12,300 × g) for 7 min. An aliquot (900 μL) of the
supernatant was transferred into a 4-mL glass screw-top vial and dried at room temperature
under nitrogen flow. After drying, the contents of the glass vial were reconstituted with
200 µL of HPLC mobile phase A (10 mM ammonium formate in water). The solution was
thoroughly mixed, filtered with a 0.22-µm tetrafluoropolyethylene membrane syringe
filter, and transferred into a 2-mL HPLC vial with glass insert (200-µL) for analysis.
3.2.4. HPLC-MS/MS Analysis
HPLC was performed on a Shimazu UFLC with model LC-20ADXR controller.
The column used for chromatography was an Agilent polymeric reversed- phase column,
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Zorbax eclipse-XDB C18 (4.6 × 150 mm, 5.0 μm, part #: PN 993967-902). The
chromatographic separation was achieved using isocratic elution at a flow rate of 1 mL/min
at 60% B (10 mM ammonium formate in methanol, 5:95) held constant for 5 min. The
column was equilibrated for 1 min and 10 µL sample volume was injected for HPLCMS/MS analysis.
For MS analysis, a tandem mass spectrometer (Sciex Q-Trap 5500 MS) equipped
with an electrospray ionization interface in the negative polarity mode was used to detect
MESNA. Optimization of MS conditions was accomplished by direct infusion of a standard
solution of MESNA into the spectrometer at a flow rate of 10 µL/min. Nitrogen (50 psi)
was used as the curtain and nebulization gas. The ion spray voltage was 4,500 V, the source
temperature was 500 °C, and both the nebulizer (GS1) and heater (GS2) gas pressures were
90 psi. The collision cell was operated with an entrance potential of 10.0 V and an exit
potential of 11.0 V at a “medium” collision gas flow rate. Multiple reaction monitoring
mode (MRM) was used for MESNA analysis. Table 3.2 shows the MS/MS MRM operating
parameters for the method. Data analysis was completed using the Analyst software
program.

51

Table 3. 2 MRM transitions, optimized collision energies (CEs), cell exit potentials (CXPs) and declustering potentials (DPs) for the
detection of MESNA and 3-MPS by MS/MS analysis.
Compounds
MESNA (quantification)
MESNA (identification)
3-MPS (quantification)
3-MPS (identification)

Q1 (m/z)
140.40
140.40
154.70
154.70

Q3 (m/z)
79.9
138.9
80.0
93.9

Time (ms)
100
100
100
100

CE (V)
-25.29
-21.20
-43.25
-24.10

CXP(V)
-9.27
-9.00
-14.09
-7.20

DP (V)
-24.24
-16.11
-89.93
-51.02
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3.2.5. Calibration, quantification, and limit of detection
The developed method was validated based on the bioanalytical method
development guidelines provided by the Food and Drug Administration (FDA).(103, 161, 185)
The limit of detection (LOD) of MESNA, which is described as the lowest concentration
of MESNA that reproducibly produced a signal-to-noise (S/N) of 3, was obtained by
analyzing multiple concentrations of MESNA in plasma below the lower limit of
quantification (LLOQ) using the developed HPLC-MS/MS method. The noise was
calculated as peak-to-peak noise in the blank samples over the retention time of MESNA.
To define the linear range and estimate the accuracy and precision of the method,
stock solution of MESNA (10 mM) in water, was diluted in rat plasma to prepare the
calibration standards (0.05, 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100 and 200 μM) and qualitycontrol (QC) standards (3, 30, and 70 μM). The QC standard concentrations were not
included in the calibration range. Each calibration standard was prepared in triplicate and
QC standards were prepared in quintuplicate. The calibration curve was plotted using the
average peak area signal ratios of MESNA to IS plotted as a function of calibrator
concentration. Peak areas of MESNA and IS were obtained by manual integration. To
obtain the linearity, accuracy, and precision of the calibration standards, both nonweighted
and weighted (1/x and 1/x2) calibration curves were constructed using linear least squares.
Since the coefficient of variation (R2) does not accurately quantify goodness-of-fit (GOF)
throughout the calibration range,(186) Percent Residual Accuracy (PRA) was used together
with the coefficient of determination to determine GOF with PRA values ≥90% indicating
an excellent fit.(162,

187)

A weighted 1/x2 fit was chosen as the best model to fit the

calibration data based on R2 and PRA. The LLOQ and upper limit of quantification
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(ULOQ) were determined using the inclusion criteria of <15% relative standard deviation
(%RSD, as a measure of precision) and a percent error (as a measure of accuracy) of
100±15%. The percent error was calculated based on the comparison of the MESNA
concentration back-calculated from the calibration curve to the nominal MESNA
concentration of the QC standard.
To evaluate the intraassay and interassay accuracy and precision of the method,
quality control (QC) standards of 3 μM (low QC), 30 μM (medium QC), and 70 μM (high
QC) were analyzed over three days (within 5 calendar days). A calibration curve was
constructed each day together with the QCs. Intraassay (within same day) precision and
accuracy were calculated for each individual day, and interassay precision and accuracy
were calculated by comparing the data gathered over three separate days (over 3 days
within 5 calendar days).
3.2.6. Recovery, matrix effect, and selectivity
Assay recovery of MESNA was determined by analyzing low, medium, and high
QC standards of MESNA from spiked plasma and aqueous samples. Low, medium, and
high QC standards were prepared in quintuplicate for both matrices. Recovery was
determined as the percentage of the average analyte peak area from spiked plasma which
went through the sample preparation procedure to the average peak area or signal ratio of
aqueous QC standards containing MESNA reconstituted in mobile phase. Internal standard
was not used to calculate recovery. The matrix effect for MESNA analysis was determined
by comparing the slopes (m) of calibration curves created in both aqueous and plasma
matrices. The value of the slope ratio (plasma slope/aqueous slope) from the calibration
curves was used to quantify the matrix effect. A slope ratio (mplasma/maq) equal to one
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indicates the matrix does not affect the analysis. On the other hand, mplasma/maq greater than
one indicates multiplicative enhancement of the analyte in plasma, whereas slope ratio less
than one indicates suppression of the analyte signal by plasma matrix. The efficacy of the
IS to correct for the matrix effect was evaluated by comparing the ratio of mplasma/maq of
non-IS corrected calibration curves with the IS-corrected calibration curves. To evaluate
the selectivity of the method, we confirmed the absence of interfering compounds via
evaluation of prominent signals above the baseline in blanks over the retention time of
MESNA by comparing several blank rat plasma and MESNA-spiked rat plasma samples.
3.2.7. Stability
The short- and long-term storage stability of MESNA were evaluated by analyzing
low (LQC) and high QC (HQC) MESNA-spiked plasma samples stored at different
temperatures and multiple storage times. The stability of MESNA was determined as a
ratio of MESNA signal at time(t) to the signal at time “zero”, expressed as a percentage.
MESNA was considered stable in plasma at a specific storage condition if the signal was
within 10% of the initial signal. For short-term stability of MESNA, both low and high
QCs were assessed over 24-hr, both in the autosampler (at 15 and 5°C) and on the benchtop
(at room temperature). The autosampler stability was assessed twice on different days by
placing triplicates of low and high QC on the autosampler of the HPLC at 15 and 5°C and
analyzing them at approximately 0, 1.5, 2, 4, 8, 12 and 24 hr following preparation.
Benchtop stability was evaluated by placing low and high QCs plasma samples on the
benchtop (room temperature) for 0, 1, 2, 4, 8, 12 and 24 hr and analyzing them after each
time point utilizing the procedure above (Section 3.2.3). The IS was added after storage
and prior to sample preparation to correct for the day-to-day instrument signal variation.
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For freeze-thaw (FT) stability, four sets of LQCs and HQCs were prepared in triplicates
without IS. One set of both QCs was analyzed in triplicate immediately, while the other
sets were stored at -80 °C. For each cycle, all QC standards were thawed unassisted at room
temperature. One set of the thawed QCs was analyzed in triplicate after adding IS to
evaluate the first cycle FT stability and the remaining two sets of QCs were again stored at
-80 °C. This procedure was repeated twice more to evaluate the remaining two freeze-thaw
cycles. A total of three freeze-thaw cycles were evaluated. For the long-term stability
studies, QC standards were stored at various storage conditions (-80, -20, 4 °C, and room
temperature) and analyzed over 30 days (at 0, 1, 5 10, 15, and 30 days). IS was added to
each storage stability standard after storage to correct for day-to-day variation in instrument
sensitivity.
3.3. Results and Discussion
3.3.1. HPLC-MS/MS Analysis of MESNA
The HPLC-MS/MS method developed for analysis of MESNA from rat plasma
features quick and simple sample preparation and analysis. The sample preparation is
comprised of 4 simple steps: 1) protein precipitation, 2) centrifugation, 3) transfer and
drying of the supernatant, and 4) reconstitution in aqueous mobile phase for HPLC-MS/MS
analysis. This quick plasma sample preparation is vital to minimize the potential for
conversion of MESNA to diMESNA. The simple sample preparation procedure also allows
for analysis of about 90 samples within 24-h period compared to some existing methods.
For example, Mare et al.(166) reports an HPLC-FLD method for MESNA utilizing
derivatization with Thioglo TM 3 solution, but requires a 33 min sample preparation
procedure and 7 mins analysis time. Verschraagen et al.(181) also reports an HPLC-ECD
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method with sample preparation time of 35 min and chromatographic run time of 12.5
min.(181) Conversely, our method utilizes a shorter sample preparation and analysis time of
15 and 5 min respectively. The mass spectra of MESNA and 3-MPS produced by ESI (−)MS with the most abundant ions identified are shown in Fig. 3.1A and B, respectively. The
m/z ratios of 140.40 and 154.70 correspond to the molecular ions ([M–H]−) of MESNA
and 3-MPS, respectively. For MESNA, the 140.40→79.9 and 140.40→138.9 transitions
were selected as the quantification and identification transitions, respectively. For the
internal standard, 3-MPS, the 154.70→80.0 and 154.70→138.9 transitions were selected
as the quantification and identification transitions, respectively.
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Figure 3. 1 ESI (-) product ion mass spectra of MESNA (A) and 3-MPS (B) with
identification of the abundant ions. Molecular ions of MESNA and 3-MPS [M–H] −
correspond to 140.40 and 154.70 m/z, respectively. Insets, structures of MESNA (A) and
3-MPS (B) with abundant fragments indicated.
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Figure 3. 2 Representative HPLC-MS/MS chromatograms of spiked (5 μM) and nonspiked MESNA and (B) 3-MPS (IS) in rat plasma. The chromatograms show signal
response to the MRM transitions of MESNA (140.40 → 79.9 and 140.40 → 138.9 m/z) and
3-MPS (150 → 80.0 and 154.70 → 93.9 m/z).

HPLC-MS/MS chromatograms of MESNA and its internal standard, 3-MPS,
prepared from spiked plasma are shown in Figures 3.2A and B, respectively. Both peaks
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eluted at approximately 1.3 min. Our method produced excellent selectivity for both
MESNA and 3-MPS with no other prominent peaks present in the chromatograms. The
selectivity of the method addresses a disadvantage of multiple methods listed in table.
3.3.2. Linear range, calibration, and limit of detection
The linearity of the method was determined by constructing calibration curves over
the initial concentration range of 0.05‒200 μM. Based on the linear range inclusion criteria
for accuracy and precision, the 0.05, 0.1 and 0.2 μM calibrators were excluded. Thus, the
linear range of the method was 0.5 μM (LLOQ) to 200 μM (ULOQ) as best defined by 1/x2
weighted linear regression. All the calibrators within the linear range had individual PRAs
>90% indicating an excellent GOF of the calibration equation for each calibrator. This
linear range spanned over three orders of magnitude, which is outstanding for bioanalytical
methods.(14, 188) This wide linear range is very beneficial when it comes to pharmacological
studies where analysis of wide range of MESNA concentrations may be necessary.
Additionally, the method showed an excellent LOD of 20 nM.
Calibration curves were constructed over a period of three days to determine the
consistency of the calibration. As shown in Table 3.3, the R2 and PRAs were consistent
and excellent. PRAs were >90% and R2 were >0.999 over the period of three days, but the
calibration equation varied significantly. Therefore, the calibration curve should be
prepared on the day of analysis.
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Table 3. 3 Linear equations, coeﬃcients of determination (R2), and percent residual accuracy (PRA) for calibration curves created over
3 days.
Day
1
2
3

Equation
y =10.0428x -1.345
y = 5.8609x - 0.970
y = 9.9436x - 0.511

R2
0.9932
0.9943
0.9998

PRA (%)
96
93
97
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3.3.3. Accuracy and precision
The accuracy and precision of the method were estimated by quintuplicate analysis
of low, medium, and high QCs on three different days within 5 calendar days (Table 3.4).
The accuracy and precision of the method were excellent for all the 3 days tested. The
intraassay and interassay accuracies were both 100±10% of the nominal QC
concentrations. The accuracy and precision of the method were remarkable, with all QCs
producing %RSDs <10% and accuracies of 100 ± 10% while within the FDA-acceptable
range for method validation from a biological matrix.(189-191)
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Table 3. 4 The intra- and interassay accuracies and precisions of MESNA analysis from spiked rat plasma by HPLC-MS/MS.
Intraassay
Conc
(µM)

a

Accuracy (%)
Day 1

Day 2

3

100±0.4

100±2.0

30

100±5.9

100±5.9

70

100±1.9

100±9.6

Interassay
Precision (%RSD)

Day 3
100±7.0
100±3.2
100±0.3

Aggregate of three days of QC method validation (N = 15)

Accuracy
(%)a

Precision
(%RSD)a

Day 1

Day 2

Day 3

8.7

4.6

8.8

100±7.0

<8.8

9.0

8.6

4.2

100±5.9

<9.0

7.8

4.0

6.5

100±9.6

<7.8
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3.3.4. Matrix effect, recovery, and stability
The evaluation of matrix effects reveals the direct or indirect alteration of response
owing to the presence of interfering substances in the plasma matrix. To determine the
effect of the plasma matrix on the analysis of MESNA, calibration curves were constructed
in both plasma and aqueous samples. The slopes of standard curves of MESNA spiked in
aqueous solutions and plasma (mplasma/maq) were compared to obtain the matrix effect value
of 0.96, showing only a minor matrix effect for the analysis of MESNA in plasma. The
recoveries for low, medium, and high QCs of MESNA in rat plasma were 90%, 91%, and
99% respectively. Addition of internal standard corrected for incomplete recoveries for
low, medium, and high QCs to produce 97%, 95%, and 100% signal accuracy, respectively.
Since the percent recovery determined in this manner is a combination of matrix effect and
recovery. The minor matrix effect in rat plasma does slightly contribute to recoveries less
than 100%.
For the benchtop stability, MESNA was stable in rat plasma for the 24-hr period tested.
Conversely, MESNA was unstable in prepared samples after 2 hr in the autosampler at 15
°C. Moreover, while samples were stored on the autosampler at 15 °C, both MESNA and
the IS signals were inconsistent, leading to the IS not correcting for the loss of MESNA.
In an attempt to stabilize the MESNA and 3-MPS in the autosampler, the autosampler was
cooled to 5 °C. At this temperature, the stability of MESNA was greatly improved with
MESNA producing stable signals for at least 24 hr. Because the IS is added to samples
prior to storage on the autosampler, the loss of MESNA signals in the autosampler at 15
°C may be due to the instability of the IS at higher temperatures or reaction of the IS with
MESNA at 15 °C. For freeze-thaw stability, MESNA stability was excellent in plasma (-
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80 °C) over the three freeze-thaw cycles evaluated with not more than 10% deviation from
the control. The long-term stability of MESNA was evaluated at multiple storage
temperatures. For MESNA samples stored at room temperature and 4 °C, stability was
within 10% of the initial signals for 5 days and 2 weeks, respectively, and MESNA signals
for both high and low QCs decreased rapidly after 15 days of storage for both storage
conditions. Conversely, MESNA showed excellent stability (i.e., not more than 10%
deviation from the control) in plasma when the sample was frozen (i.e., at both -20 °C and
-80 °C) for at least 30 days (longest time period tested). This is consistent with the results
obtained by Verschraagen et al.(192) who showed that MESNA stored at −20°C in
deproteinized plasma was stable for at least 35 days. Overall, based on the results of the
stability studies, we recommend that when storage is necessary, plasma samples should be
stored at either -20 °C or -80 °C and can be thawed and refrozen at least three times for
analysis. If samples are to be analyzed within 15 days, they can be stored at 4 °C. Once
samples are prepared for the autosampler, they should be kept at 5 °C until analyzed.
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Figure 3. 3 HPLC-MS/MS chromatogram from the plasma of MESNA-treated rats and rat
plasma obtained prior to MESNA treatment. The chromatograms represent signal response
to MRM quantification transition of MESNA (140.40 → 79.9 m/z).
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3.3.5. Analysis of MESNA in Treated Animals
The developed method was used to analyze plasma from MESNA-treated rats at
different time points. Chromatograms from HPLC-MS/MS analysis of the plasma of rats
treated with MESNA and rat plasma obtained prior to treatment are shown in Figure 3.3.
In the plasma of treated rats, MESNA was detected as a major peak eluting at 1.30 min.
This result shows the applicability of the method for analysis of MESNA-treated animals,
and consequently verified the selectivity and usefulness of the method for analysis of
MESNA from rat plasma.
3.4. Conclusion
A simple and sensitive HPLC-MS/MS method for the determination of MESNA in
plasma was developed. The method presented was accurate and precise and showed the
ability to analyze MESNA from plasma of treated animals. This technique will allow for
simple and rapid analysis of MESNA for further development of this important therapeutic.
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Chapter 4. Investigation of the Interaction between Sulfur Mustard Analogue, 2Chloroethyl Ethyl Sulfide and Methimazole for Possible Reaction Product
Formation

4.1. Introduction
Sulfur mustard (bis (2-chloroethyl) sulfide, (SM)) is a powerful bifunctional alkylating
compound and a well-known vesicating (blistering) and warfare agent.(193-196) It causes
severe damage to skin, eyes, and respiratory tract.(28, 197, 198) SM was first used during World
War I and has since been used in several conflicts including the Iraq-Iran war in 1988 and
Syria in 2019.(15, 199) It remains a major threat for use in battlegrounds and terrorist actions
against both civilian and military targets because of its easy accessibility, inexpensive
manufacture and storage, and lack of effective countermeasures against its toxicity.(200, 201)
Besides the peril of SM being used in a possible warfare or terrorist attack, there is also a
risk of accidental exposure due to the inappropriate disposal of old weaponry containing
SM.(202)
Exposure to SM causes many devastating effects such as ocular and dermal injury,
respiratory tract damage, reproductive and developmental toxicity, and gastrointestinal and
hematological damage.(39) The vesicating effects of SM lead to inflammation and extensive
blistering of the skin, an important primary target organ due its large surface area.(39, 194) In
addition, SM is known as an efficient carcinogen in humans in relationship to its DNA
damaging properties.(203) There has also been reports made on induction of internal cancers
in humans exposed to SM.(203, 204) The toxicity of SM is attributed to its alkylating nature.
SM undergoes intramolecular cyclization to form the electrophilic ethylene episulfonium
intermediate and liberation of the free chloride ion.(193) The cyclic sulfonium ion, in turn,

70

alkylates many cellular macromolecules, including DNA, RNA, and proteins.(205) Also, SM
can lead to the depletion of cellular glutathione (GSH) and antioxidant enzymes such as
superoxide dismutase, catalase, and glutathione peroxidase, resulting in the accumulation
of reactive oxygen species (ROS) followed by lipid peroxidaion, protein oxidation, and
eventually DNA damage.(61,
SM,(201,

207, 208)

206)

Due to the requirement of containment facilities for

2-chloroethyl ethyl sulfide (CEES; a monofunctional SM analog) is

extensively used to study the mechanisms of SM-induced toxicity, including both direct
and oxidative DNA damage.(195, 209, 210) Numerous studies have shown that CEES also
alkylates nucleophilic groups in macromolecules and causes an increase in oxidative DNA
damage, lipid peroxidation, protein oxidation, and ROS production, in both animal and cell
culture(61, 211, 212)
Currently, there is no antidote for treating SM poisoning. Despite extensive research
efforts, little progress has been made on developing effective treatment regimens, and
victims often require extended hospitalization. More researched areas of therapeutics for
SM poisoning includes biotherapy and transplantation. Even So, many of these proposed
therapies have disadvantages like unwanted toxic effects and counterproductive biological
impacts. Hence, strategies to ameliorate the effects of such an attack is critically
important.(35, 213)
There is increasing evidence that a significant fraction of the SM dose remains
biologically active within the victim’s body for several days after exposure,(111, 214, 215) a
window of opportunity exists to administer a “scavenger” to an affected individual
instantly and in the days following exposure in hopes of reducing harm by neutralizing
unreacted SM. For this strategy to be effectively implemented, it is essential to identify a
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candidate compound with excellent affinity towards SM and very low toxicity. N-acetyl
cysteine (NAC) and glutathione(62) have been tested as scavengers for SM toxicity due to
their known antioxidant properties, biological prevalence, and potential scavenging ability
but several studies concluded that their mechanism of action proceeds through pathways
disparate to scavenging.(63)

Methimazole, an antithyroid drug has been use as a scavenger to combat the effects of
sulfur mustard poisoning. Recent cell culture studies have shown that methimazole, is able
to reduce cell death in CEES-affected cell lines when treated with methimazole. However,
there are no studies on the mechanism underlying the scavenging ability of methimazole
for CEES in preventing cell death. Due to the nucleophilicity of methimazole, we expect
that it will react with CEES to form 2-(2-(ethylthio)ethylthio)-1-methyl-1H-imidazole
(ETTMI) which in effect will prevent the action of CEES on affected areas. The aim of this
research was to investigate the interactions between methimazole and CEES for a possible
formation of 2-(2-(ethylthio)ethylthio)-1-methyl-1H-imidazole.
4.2 Materials and Methods
4.2.1 Materials
All reagents and solvents were at least HPLC grade, unless otherwise stated. Formic
acid and acetonitrile were purchased from Fisher Scientific (Fair Lawn, NJ, USA). CEES
and methimazole were purchased from Sigma-Aldrich. CEES stock solution (1 M) was
prepared in anhydrous ethanol. Stock solution of methimazole (1M) was prepared in PBS
buffer. All stock solutions were stored at 4 °C.
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4.2.2 Cell culture
Human keratinocyte epithelial HaCaT cells were cultured and used in this study.
Briefly, HaCaT cells were grown in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, 10,000
μg/mL streptomycin and 0.5 µg/ml amphotericin B at 37 °C equilibrated with 5% (v/v)
CO2 in humidified air.
4.2.3 MTT assay
HaCaT cells were seeded in 96-well plates at a density of 1.5-2.5 x 104 cells/100
µL cellular media per well. The plates were incubated overnight and treated with CEES
(i.e., the SM stimulant), methimazole (i.e., the scavenger candidate) or both at the indicated
working concentrations, eight wells per condition. CEES treatments were added within 15
s of mixing the treatment dilution in cell media to keep dosage effects consistent between
trials, and methimazole treatments were added 15 s following CEES treatments to mimic
a post-exposure response. CEES and methimazole concentration were (1 mM) and (2 mM)
respectively following scavenger addition. Analysis was performed following incubation
for 4, 8, 24, and 48 hr. To prevent unwanted reactions between the sulfur-containing
scavengers and the MTT reagent, PBS (200 µL) was added to wash each well to remove
scavenger molecules. The wells were subsequently filled with 100 µL/well of cell media
and 20 µL/well of MTT reagent. Plates were incubated for 1.75-2 hr and cell lysates were
collected for detection of ETTMI using HPLC-MS/MS.
4.2.4 Sample Preparation
To CEES-methimazole cell lysate (900 µL), acetone (3 mL) was added to
precipitate macromolecules. The sample was vortexed 3-4 times right away, and then
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centrifuged at 2,000 rpm for 10 min. An aliquot of the supernatant (approximately 3 mL)
was then transferred into a 4-mL glass screw-top vial and dried under nitrogen at room
temperature. The dried samples were then reconstituted with 500 μL of 70% aqueous
acetonitrile, mixed thoroughly, filtered with a 0.22-μm tetrafluoropolyethylene syringe
filter, and analyzed using HPLC−MS/MS.
4.2.5 HPLC-MS/MS analysis of ETTMI
Liquid chromatography analysis was performed on a Shimazu UFLC with LC20ADXR controller. The column used for chromatography was an Agilent polymeric
reversed-phase column, Zorbax eclipse-XDB C18 (4.6 × 150 mm, 5.0 μm, part #: PN
993967-902). The chromatographic separation was achieved using isocratic elution at a
flow rate of 1 mL/min at 70% B held for 7 min. Mobile Phases A and B were 0.1% formic
acid in water and acetonitrile, respectively. The column was equilibrated for 1 min and a
sample volume of 10 µL was injected for HPLC-MS/MS analysis. For MS analysis, a
tandem mass spectrometer (Sciex Q-Trap 5500 MS) equipped with an electrospray
ionization interface in the positive polarity mode was used to detect CEES-methimazole
adduct. Optimization of mass spectrometric conditions was accomplished by direct
infusion of a CEES-methimazole reaction solution into the spectrometer at a flow rate of
10 µL/min. After infusion of CEES-methimazole adduct solution into the ESI, molecular
ion of m/z 204.30 ([M+H]+) was identified. Multiple reaction monitoring (MRM)
parameters for ETTMI was optimized and are outlined in Table 4.1. Nitrogen (50 psi) was
used as the curtain and nebulization gas. The ion spray voltage was 4,500 V, the source
temperature was 500 °C and both the nebulizer (GS1) and heater (GS2) gas pressures were
90 psi. The collision cell was operated with an entrance potential of 10.0 V and an exit
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potential of 11.0 V at a “medium” collision gas flow rate. The total mass spectrometry
acquisition time was 7 min.
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Table 4. 1 MRM transitions, optimized collision energies (CEs), cell exit potentials (CXPs), and declustering potentials (DPs) for the
detection of ETTMI by MS/MS analysis.
Compounds

Q1 (m/z)

Q3 (m/z)

Time (ms)

CE (V)

CXP(V)

DP (V)

ETTMI (quantification)

204.30

89

100

44.11

17.23

12.97

ETTMI (identification)

204.30

61

100

43.65

38.05

29.00
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4.3. Results and Discussion
4.3.1 Formation of 2-(2-(ethylthio)ethylthio)-1-methyl-1H-imidazole (ETTMI)
2-chloro-ethyl ethyl sulfide (CEES), the monofunctional analog of SM is a strong
alkylating agent that alkylates macro molecules, especially DNA. Just like SM, CEES’s its
strong electrophilic character confers on it a high affinity towards various nucleophilic
molecules.(216) Methimazole is a distinctive scavenger that contains a thiodiamine
functional group. Its central carbon is surrounded by two amine groups and a thiol. The
thiodiamide functional group has the ability to tautomerize as well as has close proximity
of multiple promising nucleophilic functional groups making it an excellent scavenger or
molecule to react with CEES.(217)
In this study, we investigated the interaction between CEES and methimazole for a
possible product formation. Methimazole’s reaction with CEES forms ETTMI and
prevents the akylating action of CEES on cell lines which could result in cell death. Figure
4.1 shows the proposed reaction scheme for the reaction of CEES with methimazole to
form ETTMI. In summary, the 2-chloroethyl side chain of CEES molecule undergoes
intramolecular cyclization where the chlorine act as leaving group and a sulfonium ion is
formed. The sulfonium cation then reacts with the nucleophilic sulfur group on
methimazole to form ETTMI which prevents further action of CEES on the nucleophilic
macromolecules.
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Figure 4. 1 Reaction pathway for the formation of ETTMI from the reaction CEES with
methimazole. CEES is proposed to react with methimazole to form 2-(2(ethylthio)ethylthio)-1-methyl-1H-imidazole (ETTMI) which prevents the action of CEES
on affected cells.

4.3.2 Confirmation of the formation of CEES-methimazole adduct.
To confirm the formation of CEES-methimazole adduct from in-vitro samples,
CEES-affected HaCat cell lines were treated with methimazole, and analytical methods
were developed to detect the proposed reaction product. The mass spectra of ETTMI as
shown in Figure 4.2 is produced by ESI (+)-MS with the molecular ion structure ((M + H)
+

, m/z = 204.30) and its abundant fragments identified. The optimized MS/MS parameters

for the detection of ETTMI are shown in Table 1. Figure 4.3 shows the HPLC−MS/MS
chromatograms of ETTMI analyzed from spiked cell culture media and cell lysate. ETTMI
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was detected from both spiked media and cell lysates as shown in the chromatograms at
about 1.25 min. Figure 4.4 shows the bar graphs of ETTMI detected from PBS buffer,
media, and cell lysates at the different incubation periods. Comparing ETTMI from PBS
buffer to media and cell lysates, we saw a greater formation (about 85%) of ETTMI from
media and cell lysates indicating that methimazole reacts with CEES preferentially to
components in the matrix. This was consistent at the different incubation periods. The
detection of ETTMI from both spiked media and cell lysates at the different time points (4,
8, 12, and 24 hr) conclusively confirms the formation of a product from reaction between
CEES and methimazole. This supports the reaction scheme shown in Figure 4.1 and
confirms the scavenging ability of methimazole for CEES as a possible pathway for
reversing the toxic effects of SM.
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Figure 4. 2 ESI (+) product ion mass spectra of with identification of the ETTMI abundant
ions. Molecular ion of ETTMI [M+H] + corresponds to 204.30. Insets, structure of ETTMI
with abundant fragments indicated.
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Figure 4. 3 HPLC−MS−MS chromatograms ETTMI from spiked media and from cell
lysates is presented.

7

81

Average Peak area(x 106)

4

3

2

1

0
Blank
PBS

4 hrs

8 hrs
24 hrs
Time (hrs)

Media

48 hrs

Cell lysates

Figure 4. 4 A bar graph showing the comparison of ETTMI from PBS buffer, media, and
from cell lysates is presented.

4.4 Conclusion
A new product formed from the reaction of CEES with methimazole was identified
as ETTMI and an HPLC-MS/MS method for the analysis of the compound was developed.
ETTMI was successfully detected from CEES-methimazole cell lysates, hence, one of the
pathways by which methimazole scavenges CEES is by the formation of the compound,
ETTMI thereby prevents CEES from alkylating macromolecules. This prevents the toxic
effects posed by CEES in the in-vitro samples.
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Chapter 5. Conclusions, Broader Impacts, And Future Work
5.1 Conclusions
A novel MIC-tyrosine adduct, PMC was found based on the interaction of tyrosine
and MIC utilizing base hydrolysis and a simple HPLC-MS/MS method was successfully
developed and validated to analyze the novel compound, PMC. The detection of PMC in
both MIC-spiked rat Hb precipitate and Hb isolated from MIC exposed rats, indicates that
PMC is a promising biomarker of MIC exposure. A novel compound ETTMI was
identified based on the reaction of methimazole with CEES and an HPLC-MS/MS method
was developed for its analysis. The detection ETTMI from invitro samples supports the
chemical scavenging ability of methimazole for CEES. A simple and sensitive HPLCMS/MS method for analysis of MESNA in plasma was successfully developed and
validated. This will enhance further pharmacological studies.
5.2 Broader impacts
Exposure to TIAs can cause a spectrum of adverse health effects that range from
subclinical to immediately lethal. Hence development of technologies, research into
methods to determine their exposure, and development of effective therapeutic agents are
vital to combat the effects of TIAs exposure. The detection of the novel compound, PMC
formed from strong base hydrolysis of MIC-tyrosine can serve as a promising biomarker
of MIC exposure. It will also provide insights into sample preparation methods for MICHb adducts. Additionally, detection of ETTMI from CEES-methimazole invitro samples
could be used to characterize the chemical scavenging ability of methimazole as an antidote
for sulfur mustard poisoning. Furthermore, the method for the analysis of MESNA showed

83

here will allow for further development of MESNA as a promising scavenger for MIC and
sulfur mustard exposure and will enhance further pharmacological research.
5.3. Future work
Future work should include the application of PMC method to analyze PMC from
more animals exposed to MIC by IV and compare to exposure by inhalation. More animal
studies should be performed to confirm the effectiveness of PMC as a diagnostic marker.
Also, a pure standard of ETTMI should be synthesized for further validation of the
developed method. Lastly, the developed method for MESNA should be applied to other
matrices like urine, etc.
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